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In the complete genome sequences of Bacteroides fragilis NCTC9343 and 638R, we have
discovered a gene, ubb, the product of which has 63% identity to human ubiquitin and cross-
reacts with antibodies raised against bovine ubiquitin. The sequence of ubb is closest in identity
(76%) to the ubiquitin gene from a migratory grasshopper entomopoxvirus, suggesting
acquisition by inter-kingdom horizontal gene transfer. We have screened clinical isolates of B.
fragilis from diverse geographical regions and found that ubb is present in some, but not all,
strains. The gene is transcribed and the mRNA is translated in B. fragilis, but deletion of ubb did
not have a detrimental effect on growth. BfUbb has a predicted signal sequence; both full-length
and processed forms were detected in whole-cell extracts, while the processed form was found in
concentrated culture supernatants. Purified recombinant BfUbb inhibited in vitro ubiquitination
and was able to covalently bind the human E1 activating enzyme, suggesting it could act as a
suicide substrate in vivo. B. fragilis is one of the predominant members of the normal human
gastrointestinal microbiota with estimates of up to .10
11 cells per g faeces by culture. These data
indicate that the gastro-intestinal tract of some individuals could contain a significant amount of
aberrant ubiquitin with the potential to inappropriately activate the host immune system and/or
interfere with eukaryotic ubiquitin activity. This discovery could have profound implications in
relation to our understanding of human diseases such as inflammatory bowel and autoimmune
diseases.
INTRODUCTION
The highly conserved protein-modifier ubiquitin has, to
date, only been found in eukaryotes, where tagging of
proteins with ubiquitin (ubiquitination) is intrinsic to
control of diverse processes central to cell function. The
first role identified for ubiquitin was the regulation of
intracellular proteolysis via the 26S proteosome, in which
ubiquitin becomes covalently bound to a substrate that is
subsequently targeted for degradation (Hochstrasser,
2009). The first step of ubiquitination in eukaryotes is
the covalent attachment of ubiquitin to the cognate
activating enzyme E1, initially by adenylation of the C
terminus of ubiquitin followed by formation of a thioester
bond with the active site cysteine of E1. The covalently
attached ubiquitin is subsequently transferred to the active
site cysteine of the ubiquitin-conjugating enzyme E2,
followed by formation of an isopeptide bond with the
final substrate mediated by the ubiquitin ligase enzyme E3
(Komander, 2009).
It is now recognized that post-translational regulation by
ubiquitination also plays an important role in modification
of protein function, including cell cycle progression,
membrane protein endocytosis, intracellular trafficking,
ribosome biogenesis, signal transduction, DNA repair,
stress responses, chromatin-mediated regulation of tran-
scription and antigen presentation.
Ubiquitin is also a major factor involved in development
and function of both the innate and adaptive immune Abbreviations: GI, gastrointestinal; OMV, outer membrane vesicle.
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therefore implicated in a wide range of diseases, including
cancer, cardiac disease, neurodegenerative disorders and
type 2 diabetes (Schwartz & Ciechanover, 2009; Rodrı ´guez
et al., 2009; Komatsu & Ichimura, 2010; Vereecke et al.,
2009). Immune surveillance for invading pathogens is also
controlled by ubiquitin. Extracellular pathogens are
recognized by Toll-like receptors that activate a cascade
leading to phosphorylation of IkBa, the inhibitor of NF-
kB. Ubiquitination and subsequent proteolytic degradation
of IkBa releases NF-kB for entry into the nucleus where it
activates transcription of pro-inflammatory associated
genes (Karin & Ben-Neriah, 2000). Similarly, regulatory
events triggered by nucleotide oligomerization domain-like
receptor recognition of intracellular pathogens involve
ubiquitination (Shaw et al., 2008). In addition, Salmonella
enterica internalized by macrophages is recognized by a
cytosolic mechanism that stimulates direct polyubiquitina-
tion of bacterial surface proteins with subsequent recruit-
ment of the proteosome, followed by destruction of the
invading prokaryote and presentation of derived peptides
to class I major histocompatibility complex molecules
(Perrin et al., 2004).
While the evolutionary origin of eukaryotic ubiquitin is
hypothesized to be rooted within a common prokaryotic
ancestor, structural homologues of ubiquitin identified in
bacteria do not have sequence similarity, apart from two
terminal glycine residues; examples include the MoaD and
ThiS proteins in Escherichia coli involved in thiamine and
molybdopterin biosynthesis, respectively. These proteins
are not involved in proteolysis but do utilize chemistry
similar to ubiquitin conjugation, i.e. formation of a
thioester bond between the C-terminal glycine and a
cysteine catalytic residue in a complementary activating
enzyme (Hochstrasser, 2009).
The primary mechanisms for regulation of protein half-life
and translation quality control in bacteria do not involve
homologues of eukaryotic ubiquitin. In E. coli the N-
terminal rule pathway dictates the stability of a polypeptide
via an adaptor protein, ClpS, which targets degradation by
the ClpAP protease (Erbse et al., 2006). Prematurely
terminated translation products are marked at the C
terminus with an 11 amino acid SsrA tag that directs the
polypeptide for degradation by either ClpXP or ClpAP
(Gottesman et al., 1998). The analogous N-terminal rule
pathway in eukaryotes uses the specificity of a class of
ubiquitin E3 ligases, the N-recognins, to direct proteolysis
by the proteosome (Tasaki et al., 2005). A protein-tagging
system that functions in a similar manner to the ubquitin–
proteosome pathway has been identified in Mycobacterium
tuberculosis; however, the Pup protein that becomes
covalently attached to proteins destined for digestion does
not share sequence homology with eukaryotic ubiquitin
(Pearce et al., 2008).
We now report evidence of horizontal gene transfer from a
eukaryotic source into a bacterium of the normal human
resident microbiota which results in expression of a
secreted protein with 63% identity to human ubiquitin.
The Bacteroidetes are predominant members of the gastro-
intestinal (GI) tract microbiota. By culture, B. fragilis
represents ~10–15% of the members of the Bacteroides
present in faeces, with estimates between 10
11 and 10
12 cells
g
21 (Patrick, 2002). B. fragilis is also the most frequently
isolated obligately anaerobic Gram-negative bacterium from
life-threatening human infections, such as intra-abdominal,
vaginal and brain abscesses (Patrick, 2002; Patrick &
Duerden, 2006), and is a major cause of anaerobic
bacteraemia, with a potential mortality rate of up to
~30% (Cheng et al., 2009). Such infections generally arise
from faecal contamination of normally uncolonized body
sites, for example, peritonitis following perforation of the
bowel (Patrick & Duerden, 2006). The discovery that
ubiquitin-positive B. fragilis is present in the GI tract,
however, could have profound implications for our under-
standing of several human diseases in which ubiquitin
malfunction is implicated, and indeed also in relation to the
development of autoimmune disease.
METHODS
Bacterial strains and growth conditions. The isolates used in this
study were B. fragilis NCTC9343, NCTC9344 and NCTC10584;
Bacteroides ovatus Queen’s University Belfast culture collection; and
clinical isolates obtained from Craigavon Area Hospital Northern
Ireland (designated ‘LS’), the Royal Victoria Hospital Northern Ireland
(designated ‘JC’), the Free University of Amsterdam kindly supplied by
J. van Doorn (designated ‘BE’), the University of Edinburgh Scotland
kindly supplied by I. Poxton (designated ‘GNAB’); and a rifampicin-
resistantmutantofanisolate fromChigaco,USA,kindlysuppliedby C.
J. Smith (638R). Identification was confirmed with the API 20A system
or PCR and sequencing. All Bacteroides strains were grown in an
anaerobic atmosphere containing 10% CO2,1 0%H 2 and 80% N2 in
either supplemented brain heart infusion broth or defined medium
(DM) (Van Tassell & Wilkins, 1978).
Molecular and immunological techniques. ubb from genomic
DNA was amplified by PCR from Bacteroides strains using Pfu poly-
merase (NEB) using ubb-specific oligonucleotide primers designed
using the NCTC9343 DNA sequence. RNA was isolated from cultures
grown in DM (samples taken at OD600 0.4, 0.8 and 1.6) using the
Qiagen RNeasy kit and quantified using a Hitachi U-2000
spectrophotometer. RT-PCR analysis of RNA samples used the
Qiagen Omniscript RT kit with 20 ng RNA template. The absence of
DNA contamination in RNA samples was confirmed by omitting the
reverse transcription step and performing the PCR amplification.
DNA was analysed by electrophoresis through 1% agarose gels
followed by staining with ethidium bromide and visualization by UV
light. The ubb deletion mutant was generated in NCTC9343 by
replacing ubb with an erythromycin resistance cassette using our
previously described method (Patrick et al., 2009).
The ubb gene was cloned as a 66His-tagged N-terminal fusion in
pTRC99a. Recombinant (r)BfUbb was purified to homogeneity by
overexpression in E. coli DH5a, followed by affinity purification using
Qiagen Ni-NTA agarose resin and gel filtration through a Superose 12
10/300 GL column (GE Healthcare). Polyclonal antiserum was
produced by inoculation of a New Zealand white rabbit with
rBfUbb conjugated to keyhole limpet haemocyanin (KLH) carrier
protein using an Imject Immunogen EDC kit with mcKLH (Thermo
S. Patrick and others
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QuilA (0.125 mg ml
21) adjuvant (Brenntag). rBfUbb (0.2 mg) was
inoculated at approximately 4 week intervals over a 6 month period
under UK Government Home Office Personal and Project Licences
and with local ethical approval. Rabbit anti-bovine ubiquitin was
obtained from Sigma-Aldrich. Whole cells for immunoblots were
electrophoresed through 12% polyacrylamide gels, transferred to a
PVDF membrane and incubated with the appropriate primary and
secondary antibodies before detection using the ECL+ chemilumin-
escent system (GE Healthcare). Supernatants from cultures grown in
DM were prepared by centrifugation, filtration through a 0.45 mm
membrane and concentrated by centrifugation through a membrane
with a 100 kDa cut-off (Amicon Ultra; Millipore). Concentrated
supernatant samples for immunoblotting were separated by electro-
phoresis through 16% SDS Tris-Tricine polyacrylamide gels.
Immunoblots were incubated with the appropriate primary antibody
followed by anti-rabbit alkaline phosphate antibody conjugate and
reacted with Sigma Fast BCIP/NBT(Sigma). Bacterial genome
sequences were viewed with Artemis and the Artemis Comparison
Tool (Carver et al., 2008).
In vitro ubiquitination. In vitro ubiquitination reactions were carried
out in25 mM HEPES and0.5 mM DTT at 37 uC for180 minandused
the fraction II HeLa conjugation kit (Boston Biochemicals) with a
biotinylated lysozyme substrate (Boston Biochemicals). Reactions
contained 4 mg Fraction II HeLa ml
21, 2.5 mg ubiquitin ml
21,
4 mM ubiquitin aldehyde, 5 mM MG-132 and an ATP regeneration
system. Reactions containing 280 mg BfUbb ml
21 were pre-incubated
at 37 uC for 15 min prior to the addition of ubiquitin. Protein samples
were separated by electrophoresis through 12% polyacrylamide gels
followed by transfer to a PVDF membrane and detection of
biotinylated lysozyme using an avidin–HRP conjugate (Boston
Biochemicals). Binding of BfUbb to human E1 was carried out in
reactions containing 390 mg BfUbb ml
21 and either 55 mgo r2 7 . 5mg
E1 ml
21 (Boston Biochemicals) in 50 mM HEPES pH 8.0 at 37 uC for
60 min. Samples were analysed on a non-reducing 12% polyacryla-
mide gel followed by transfer to a PVDF membrane and detection with
polyclonal anti-eukaryotic ubiquitin antibodies (Chemicon) and the
ECL+ chemiluminescent system (GE Healthcare).
RESULTS
A horizontally acquired gene encoding ubiquitin
in B. fragilis
The annotation of the B. fragilis NCTC9343 genome
indicates that it encodes a number of polypeptides with
similarities to human proteins (Cerden ˜o-Ta ´rraga et al.,
2005). The most striking homology, however, is found with
a putative protein encoded by BF3883 that has 63%
identity (48 of 76 amino acids) to human ubiquitin, such
as Uba52 or UbcEP2 (Fig. 1). While many of the amino
acids important for interactions with the E1 activating
enzyme are conserved in B. fragilis ubiquitin (BfUbb), it
has at least two unusual features. Firstly, it contains a signal
sequence and secondly, it does not possess the two terminal
glycine residues required for covalent interactions with the
E1 and E2 enzymes of the ubiquitin pathway (Fig. 1).
Despite the implication of its name, ubiquitin has to date
only been found in eukaryotes. BF3883 is contained within
an 11 kb sequence exhibiting a low GC content, with the
closest DNA homology to the gene being 76% identity (151/
199 bp; E55610
229) to a ubiquitin-encoding sequence,
MSV144, from a migratory grasshopper entomopoxvirus
(GenBank accession no. AF063866.1). This suggests that
BF3883 was acquired by inter-kingdom horizontal gene
transfer. Hereafter, we refer to BF3883 as ubb.
The genome sequences of two other B. fragilis strains, 638R
(isolated in the USA) and YCH46 (isolated in Japan), have
also been determined (Patrick et al., 2010; Kuwahara et al.,
2004). Strain 638R contains a similar low GC region that
includes a putative ubiquitin-encoding gene (BF638R3923)
which has 100% sequence identity to ubb. In contrast, the
YCH46 genome only has three genes from the equivalent
low GC region and does not contain ubb, suggesting that
the ubiquitin gene has been deleted. To determine the
prevalence of ubb in other B. fragilis strains, we screened a
number of isolates derived from different source materials
and different geographical locations. Analysis by PCR
demonstrated that ubb was present in clinical isolates from
patients in Edinburgh, Belfast and Amsterdam (Fig. 2).
Sequence comparison of the ubb amplicons with the
NCTC9343 sequence showed 100% conservation within
the coding region (data not shown). While there was no
obvious correlation with the presence or absence of the
ubiquitin gene and the source of the sample, this
demonstrates that the ubb gene is present in B. fragilis
strains resident in the GI tract of individuals from diverse
populations. Homologues of ubb were not found in other
Bacteroides species, by either PCR or genome sequence
analysis.
BfUbb MRFIKQVLLTITLCNIMLFALPSTVNAMQVFIKNRYGWTITLEVSPTDTVENVKQKIQDK
:                           :.:.:.  : :::::: :.::.:::: :::::
Ubc52 M---------------------------QIFVKTLTGKTITLEVEPSDTIENVKAKIQDK
10        20        30
* * ***
BfUbb EGFPPDKIRLIYGGKQMEDGRTLADYNVQKDSTILICIRDVDC
::.:::. :::..:::.::::::.:::.::.::. . .:
Ubc52 EGIPPDQQRLIFAGKQLEDGRTLSDYNIQKESTLHLVLRLRGG
40        50        60        70 
Fig. 1. A homologue of ubiquitin present in the
bacterium B. fragilis. Alignment of the pre-
dicted polypeptide encoded by the ubb gene
in B. fragilis with human ubiquitin Ubc52. The
first 28 residues of BfUbb represent the
putative signal sequence. Identical and similar
amino acids are indicated, with residues
important for interactions with E1 activating
enzyme shown in bold and with asterisks. The
two C-terminal glycine residues of Ubc52
involved in covalent attachment to the E1-
activating enzyme are underlined.
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metabolism of B. fragilis NCTC9343, as YCH46 which lacks
ubb has a slower growth rate and attains lower cell density
in stationary phase (Patrick et al., 2010), we generated a
strain in which ubb was deleted. Using our previously
described method, ubb was replaced with an erythromycin
resistance cassette (Patrick et al., 2009). The resulting
Dubb::ermF strain did not show any cell morphology
defects and had the same growth rates compared with the
parental strain in BHI-S medium and glucose defined
medium (DM). This indicates that BfUbb is not essential
for B. fragilis growth in laboratory medium, although it
may be advantageous for survival within the host.
Expression of BfUbb in B. fragilis
Since it is possible that ubb had been acquired from a
eukaryotic source, the gene may be an evolutionary relic
and may or may not be integrated adjacent to a promoter.
We confirmed active transcription of ubb in B. fragilis by
detection of mRNA using RT-PCR (Fig. 3a). Total RNA
was isolated from cultures grown in DM during early
exponential growth and upon entry into stationary phase.
RT-PCR products were detected from RNA templates
derived from both growth phases, suggesting that ubb is
transcribed by the housekeeping RNA polymerase of B.
fragilis.
We cloned and expressed the predicted processed form
of BfUbb as a 66His-tagged fusion in E. coli and used
this protein to generate rabbit polyclonal antiserum.
Immunoblotting of cell extracts from cultures grown in
glucose DM revealed BfUbb as a major protein band of
~9 kDa, plus a second band of ~12 kDa (Fig. 3b). This
pattern is consistent with cleavage of the signal peptide
having generated the abundant form of BfUbb and the
~12 kDa band, representing the holo-protein prior to ex-
port and processing. In addition, some lower-molecular-
mass bands, interpreted as degradation products were
observed. Interestingly, anti-bovine ubiquitin antibodies
cross-reacted with purified recombinant 66His-BfUbb, but
did not detect BfUbb in whole-cell extracts of B. fragilis. The
presence of a signal sequence and its apparent cleavage is
consistent with BfUbb being transported to the periplasm of
B. fragilis. To interact with the eukaryotic host, however,
BfUbb would need tobe secreted bythebacterium.B. fragilis
is known to produce outer membrane vesicles (OMVs) that
bleb fromthe cell surface (Patrick et al., 1996). To determine
whether BfUbb was potentially present in OMVs, we con-
centrated supernatants by filtration through membranes
with a 100 kDa cut-off. Immunoblotting of these concen-
trated supernatants showed the presence of a smeared band
of BfUbb that migrated close to the position of the purified
66His-BfUbb (Fig. 3c; note these samples were separated
on a higher percentage gel than that used in Fig. 3b). This
band was not detected in concentrated supernatants from
the Dubb strain (data not shown). Smeared bands are often
characteristic of glycosylated proteins. Two triplet amino
acid sequences (DTV and DST; Fig. 1) corresponding to the
consensus recognition site for B. fragilis O-glycosylation
(Fletcher et al., 2011) are present in BfUbb. The potential
glycosylation of BfUbb is being investigated.
In vitro activity of BfUbb
Since ubb is not present in all strains of B. fragilis, and
deletion of the gene in NCTC9343 did not have an
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Fig. 2. Agarose gel showing detection of the ubb gene by PCR in isolates of B. fragilis from different geographical locations.
Origins of B. fragilis samples are: PtA, peritoneal abscess; A, abscess; NpA, neoplasm abscess; PaA, perianal abscess; AbA,
abdominal abscess; UN, unknown origin. The position of the ubb amplicon is shown adjacent to the image, with DNA molecular
size markers in the first and last lanes. Note the absence of ubb in B. ovatus and some B. fragilis isolates.
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thesized that BfUbb might be a candidate protein for
interaction with the host. To examine the effect of BfUbb
on the ubiquitination pathway, we reconstituted the
reaction using HeLa cell extracts (Fraction II) and a
biotinylated lysozyme substrate. Pre-incubation of purified
66His-BfUbb with the HeLa extract, prior to addition of a
10-fold excess of eukaryotic ubiquitin, inhibited sub-
sequent covalent attachment of ubiquitin to the substrate
(Fig. 4a). This suggested that 66His-BfUbb was binding
to the activating and conjugating enzymes of the ubiqui-
tin pathway and inhibiting their catalytic functions. The
first step of ubiquitination is the covalent attachment of
ubiquitin to the E1 activating enzyme by formation of a
thioester bond with the active site cysteine. The ubiquitin
homologues encoded by all B. fragilis strains tested do not
contain a C-terminal glycine but do have a C-terminal
cysteine (Fig. 1). We hypothesized that BfUbb might form
a disulphide bridge with human E1 that would lead to its
inactivation. Under non-reducing conditions a covalent
complex could be detected between 66His-BfUbb and
human E1 by immunoblotting with anti-bovine ubiquitin
antibodies (Fig. 4b). This complex was not detected under
reducing conditions (data not shown). These data
indicated that the two proteins are capable of forming a
covalent intermediate in the absence of both ATP and a
terminal glycine residue, and suggest that BfUbb could act
as a suicide substrate leading to inactivation of E1 and
blocking of the ubiquitination cascade.
DISCUSSION
The presence of ubb only in selected strains of B. fragilis,
the similarity of BfUbb to human ubiquitin and its
antigenic cross-reactivity, as well as the potential for
BfUbb to interfere with the eukaryotic ubiquitination
pathway could have profound implications for a range of
human diseases. By culturing faeces, Bacteroides species
numbers range from 10
9 to 10
14 cells g
21, of which B.
fragilis estimates range from 4 to 14% (reviewed by
Patrick, 2002). This provides a potentially large reservoir
of an aberrant form of ubiquitin in some humans. The
resident GI tract microbiota has a well-proven role in the
normal development of the immune system. In addition,
inflammatory bowel disease is recognized as being caused
by a deficient or abnormal mucosal immune response in
individuals who are genetically susceptible, clearly related
to the presence of intestinal microbes (Marks et al., 2010;
Xavier & Podolsky, 2007). In microscopic studies of the
spatial organization of the adherent mucosal microbiota, B.
fragilis was consistently associated with the mucosal surface
of patients with inflammatory bowel disease. It was the
predominant member of the adherent mucosal biofilm,
accounting for .60% of the biofilm mass (Swidsinski et al.,
2005). It will be intriguing to determine whether, given the
intimate association of B. fragilis with the human GI tract,
BfUbb plays a role in the development of these diseases.
Furthermore, we postulate that BfUbb could be a driver of
other autoimmune diseases, as a result of generating an
7 kDa
16 kDa
6xH 9343 Dubb
12 3
(a)
ubb
PCR RT-PCR
123 4 567
500 bp
1 kb
(c) 12 3
(b)
6xH CS M
BfUbb
Fig. 3. Detecting expression of BfUbb. (a) Agarose gel showing transcription of ubb detected by RT-PCR. Lanes: 1, PCR using
genomic DNA; 2–4, PCR using RNA from cultures at OD600 0.4, 0.8 and 1.6 (indicates absence of DNA contamination); 5–7,
RT-PCR using RNA from cultures at OD600 0.4, 0.8 and 1.6. The position of ubb is indicated with an arrow. (b) Immunoblot
using rabbit anti-BfUbb polyclonal antiserum. Lanes: 1, purified 6His-BfUbb; 2, whole-cell extract of B. fragilis NCTC9343; 3,
whole-cell extract of B. fragilis Dubb. The lowest band in lane 2 represents a degradation product of BfUbb. (c) Immunoblot of
concentrated supernatant from a culture of NCTC9343 grown in DM (lane 1), compared with purified 6His-BfUbb (lane 3).
Molecular mass markers are shown in lane 2.
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proteins to which ubiqutin is bound.
The genome of B. fragilis does not encode the molecular
components required to make a proteosome equivalent to
the eukaryotic 26S proteosome; nor does it appear to
contain the activating and conjugating enzymes of the
ubiquitination pathway. The ubb gene has evolved from the
eukaryotic equivalent to encode a protein containing a
bacterial signal sequence predicted to specify export to the
periplasm; also, the C-terminal glycine residues that are
required for successful ubiquitination of target proteins in
eukaryotes are absent. This suggests that BfUbb has been
subverted by the bacterium to fulfil a unique role. So what
is the function of BfUbb? The high degree of homology
between BfUbb and human ubiquitin, with conservation of
residues important for interaction with the E1-activating
and E2-conjugating enzymes, implies that these interac-
tions are important. Although we have shown that BfUbb
can inhibit ubiquitination in vitro, it is possible that the C-
terminal cysteine residue could form a thiol-ester bond
with other amino acids on selected targets that lead to
modified protein function. The isopeptide bond formed
between eukaryotic ubiquitin and lysine residues is not the
only way that conjugates can be generated; for example, the
viral E3 ligase MIR1 can catalyse the formation of thiol-
ester bonds between ubiquitin and cysteine residues on
major histocompatibility complex I class proteins found on
the surface of cytotoxic T lymphocytes (Cadwell & Coscoy,
2005).
The periplasmic localization of BfUbb would provide a
means for mobilizing the protein into the environment. B.
fragilis produces a large number of OMVs (Patrick et al.,
1996) that are free to diffuse throughout the gut lumen.
The detection of BfUbb in supernatants that had been
concentrated through a membrane with a 100 kDa cut-off
suggests that the protein is associated with extra-cellular
macromolecular complexes. OMVs are ‘secretory vehicles’
that can deliver bacterial components to host cells and
tissues as well as other bacteria (Kuehn & Kesty, 2005;
Bomberger et al., 2009). The OMVs of B. fragilis agglutinate
erythrocytes, via sodium periodate sensitive agglutinins, and
are also known to contain degradative enzymes (Patrick
et al., 1996). The presence of unusual sphingolipids in the
B. fragilis outer membrane may allow fusion between
OMVs and eukaryotic cytoplasmic membranes that contain
sphingolipids. Alternatively, the vesicles may enter epithelial
cells by endocytosis. Ubiquitin plays a central role in the
regulation of the pro-inflammatory response. Following
exposure to a bacterial pathogen, a Toll-like receptor-
initiated signalling cascade ultimately results in the phos-
phorylation of IkB that is subsequently ubiquitinated and
degraded by the proteosome. Destruction of IkB releases
NF-kB to enable its nuclear localization and initiation of
transcription (Bhoj & Chen, 2009). If BfUbb were to enter
the cytoplasm of an epithelial cell and act as a suicide
substrate for ubiquitination, it could potentially inhibit
activation of NF-kB, thus downregulating the inflammatory
response.
BfUbb could also aid the success of B. fragilis as an
opportunistic pathogen. Many pathogenic bacteria have
evolved the ability to avoid or suppress the host immune
response by interfering with the ubiquitin-proteosome
pathway, although none of these mechanisms involve
ubiquitin homologues (Boyer & Lemichez, 2004). For
example, Yersinia pestis uses YopJ to prevent activation of
the innate immune response, Salmonella enterica serovar
Typhimurium produces a ubiquitin ligase and a deubiqui-
tinatingproteasethataresecreted intoinfected macrophages,
Lysozyme
0 180 0 180
HeLa
_BfUbb
HeLa
+BfUbb
+Ub
(a)
12 34
BfUbb
E1–BfUbb
complex
06 0 06 0 (b)
Fig. 4. In vitro activity of BfUbb. (a) Immunoblot of in vitro ubiquitination of lysozyme using HeLa cell extract in the absence
(lanes 1 and 2) or presence (lanes 3 and 4) of BfUbb. Samples were taken at the start of the reaction (0) and at 180 min (180).
Lane 2 shows the increase in molecular mass of the lysozyme substrate following covalent attachment of ubiquitin (+Ub). This
covalent modification is inhibited by the addition of BfUbb (lane 4). (b) Covalent complexes between human E1 and BfUbb,
under non-reducing conditions, were detected by immunoblotting using anti-bovine ubiquitin polyclonal serum. Two reactions
using different concentrations of E1 are shown, with time points at 0 and 60 min. Note there was some antibody cross-reactivity
with E1 at the higher concentration.
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proteases that have deubiquitinating activities (Zhang et al.,
2006; Rytko ¨nen et al., 2007; Le Negrate et al., 2008).
This discovery of a novel ubiquitin homologue in a
bacterium, which is a key member of the normal human
resident microbiota, could fundamentally alter our under-
standing of diseases that currently have an unknown
aetiology. While we postulate a possible role in inflam-
matory bowel and autoimmune diseases, mis-regulation of
ubiquitin is implicated in a wide range of diseases
including cancer, neurodegenerative disorders and type 2
diabetes. The extent to which BfUbb may or may not be
involved in any of these diseases remains to be determined,
and will require careful consideration of BfUbb-positive B.
fragilis colonization, the control of BfUbb expression and
underlying human genetic predispositions.
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